23andme - Search News

23andMe weighing up sale of company

23andMe weighing up sale of the company as cash runs dry

Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing business. A special committee of its directors’ board is considering various directions for the company in addition to a sale,

BioPharma Dive · 2d

23andMe considers a sale as cash runs low

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations and financial commitments.

newsbytesapp.com · 2d

23andMe considers sale amid financial struggles and leadership turmoil

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a staggering 98% since going public.

telecareaware.com · 1d

23andMe running low on cash, considers sale, “strategic alternatives” by Special Committee

The latest unsurprising development in 23andMe’s story is the admission, by their new board of directors, that 23andMe now does not have enough cash to continue for the next 12 months. They are now considering the following strategic alternatives: a possible sale of the company,

Seeking Alpha on MSN · 3d

23andMe says it's exploring alternatives, including a sale

Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business combination, licensing of assets,

23andMe Launches New Genetic Report on Osteoporosis

SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help ...

23andMe is exploring strategic alternatives, looking to raise capital

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

23andMe Board Explores Strategic Alternatives Amid Restructuring

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

23andMe Reports Third Quarter Fiscal Year 2025 Financial Results

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...

Stocks to Watch: 23andMe, Manhattan Associates, Nextracker

Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...

23andMe Considers Sale as Cash Runs Low

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

23andMe announces continued concerns regarding liquidity

Me (ME) ended December 31, 2024 with cash and cash equivalents of $79.4M, compared to $126.6M as of September 30, 2024 and $216.5M as of ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

23andMe weighing up sale of company

Related topics